Ascentage Pharma recently unveiled promising clinical data on the use of Alrizomadlin as a monotherapy and in combination therapies for solid tumors at ASCO 2025. The presentation highlighted the company’s optimistic outlook and strategic plans for future developments in the pharmaceutical industry. Ascentage Pharma’s forward-looking statements, as per the regulations, express the company’s views on future events and outcomes related to its operations and financial status. These statements are accompanied by a disclosure of potential risks and uncertainties, detailed in the company’s filings with the SEC and The Stock Exchange of Hong Kong Limited. The presentation serves as a milestone in Ascentage Pharma’s journey, showcasing its commitment to innovation and advancement in the field of oncology. Stay tuned for more updates on Ascentage Pharma’s groundbreaking research and contributions to the healthcare landscape.
Read more about this — here
